Amicus Therapeutics Stock In The News

FOLD Stock  USD 8.90  0.09  1.02%   
Our overall analysis of Amicus Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Amicus Therapeutics. The specific impact of Amicus Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Amicus Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Amicus Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Amicus Therapeutics Backtesting and Amicus Therapeutics Hype Analysis.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

Amicus Therapeutics Today Top News and Investor Outlook

Yahoo News
Amicus Therapeutics, Inc. (FOLD): Among the Stocks Under $10 With High Upside Potential
https://finance.yahoo.com/news/amicus-therapeutics-inc-fold-among-232926042.html
 Bullish
Yahoo News
US High Growth Tech Stocks With Strong Potential
https://finance.yahoo.com/news/us-high-growth-tech-stocks-170914833.html
 Bullish
Yahoo News
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
https://finance.yahoo.com/news/amicus-therapeutics-present-upcoming-investor-120000808.html
 Bullish
Yahoo News
Why Amicus Therapeutics, Inc. (FOLD) is the Most Oversold Pharma Stock to Buy According to Analysts
https://finance.yahoo.com/news/why-amicus-therapeutics-inc-fold-183023164.html
 Neutral
Yahoo News
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
https://finance.yahoo.com/news/folds-q4-earnings-miss-higher-153700787.html
 Bullish
Yahoo News
Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics
https://finance.yahoo.com/news/compared-estimates-amicus-therapeutics-fold-143017507.html
 Bullish
reuters
Quantum computing stocks rise as Microsoft's new chip heats up debate over technology
https://www.reuters.com/technology/quantum-computing-stocks-rise-microsofts-new-chip-heats-up-debate-over-2025-02-20/
 Bullish
Yahoo News
Amicus Therapeutics Full Year 2024 Earnings: EPS Beats Expectations
https://finance.yahoo.com/news/amicus-therapeutics-full-2024-earnings-104612459.html
 Neutral
Yahoo News
Amicus Therapeutics Inc (FOLD) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
https://finance.yahoo.com/news/amicus-therapeutics-inc-fold-q4-070503731.html
 Bullish
Yahoo News
Q4 2024 Amicus Therapeutics Inc Earnings Call
https://finance.yahoo.com/news/q4-2024-amicus-therapeutics-inc-070310205.html
 Bullish

Amicus Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Amicus and other traded companies coverage with news coverage. We help investors stay connected with Amicus headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Amicus Stock performance. Please note that trading solely based on the Amicus Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Amicus Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Amicus Therapeutics investors visualize upcoming and past events in order to time the market based on Amicus Therapeutics noise-free hype analysis.
Amicus Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Amicus earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Amicus Therapeutics that are available to investors today. That information is available publicly through Amicus media outlets and privately through word of mouth or via Amicus internal channels. However, regardless of the origin, that massive amount of Amicus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Amicus Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Amicus Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Amicus Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Amicus Therapeutics alpha.

Amicus Largest EPS Surprises

Earnings surprises can significantly impact Amicus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-06
2024-09-30-0.01-0.02-0.01100 
2024-08-08
2024-06-30-0.06-0.050.0116 
2023-11-08
2023-09-30-0.08-0.070.0112 
2021-11-09
2021-09-30-0.17-0.19-0.0211 
2023-08-08
2023-06-30-0.12-0.15-0.0325 
2023-05-10
2023-03-31-0.15-0.18-0.0320 
View All Earnings Estimates

Amicus Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Amicus Therapeutics Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
Yahoo News
12th of March 2025
Amicus Therapeutics, Inc. Among the Stocks Under 10 With High Upside Potential
at finance.yahoo.com 
Google News at Macroaxis
10th of March 2025
Amicus Therapeutics stock hits 52-week low at 8.78 By Investing.com - Investing.com Canada
at news.google.com 
Macroaxis News: globenewswire.com
6th of March 2025
In NCLA Amicus Win, D.C. Circuit Recognizes President Trumps Right to Fire Principal Offic...
at globenewswire.com 
Yahoo News
4th of March 2025
Acquisition by David Clark of 125430 shares of Amicus Therapeutics at 9.41 subject to Rule...
at finance.yahoo.com 
Gurufocus Stories at Macroaxis
27th of February 2025
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
at gurufocus.com 
Yahoo News
26th of February 2025
United Therapeutics Stock Down Despite Q4 Earnings Sales Beat
at finance.yahoo.com 
Simply Wall St News at Macroaxis
21st of February 2025
Amicus Therapeutics Full Year 2024 Earnings EPS Beats Expectations
at simplywall.st 
seekingalpha News
19th of February 2025
Amicus Therapeutics beats FY topline estimates
at seekingalpha.com 
news
14th of February 2025
Disposition of 10005 shares by Castelli Jeff of Amicus Therapeutics at 13.65 subject to Ru...
at thelincolnianonline.com 
Simply Wall St News at Macroaxis
27th of January 2025
Amicus Therapeutics shareholders have endured a 26 percent loss from investing in the stoc...
at simplywall.st 

Amicus Therapeutics Investors Sentiment

The influence of Amicus Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Amicus. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Amicus Therapeutics' public news can be used to forecast risks associated with an investment in Amicus. The trend in average sentiment can be used to explain how an investor holding Amicus can time the market purely based on public headlines and social activities around Amicus Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Amicus Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Amicus Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Amicus Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Amicus Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Amicus Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Amicus Therapeutics' short interest history, or implied volatility extrapolated from Amicus Therapeutics options trading.
When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:
Check out Amicus Therapeutics Backtesting and Amicus Therapeutics Hype Analysis.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.18)
Revenue Per Share
1.736
Quarterly Revenue Growth
0.301
Return On Assets
0.0272
Return On Equity
(0.32)
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.